PLSE — Pulse Biosciences, Inc.

Pulse Biosciences (PLSE) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $264,000 in Q4 2025, up from $86,000 in Q3 2025, driven by sales of nPulse Capital and Vybrance disposable devices.
• Cost of Product Revenue: $260,000, slightly lower than Q3.
• GAAP Net Loss: $17.4 million, an improvement from a loss of $19.4 million in Q4 2024.
• Non-GAAP Net Loss: $12.2 million, compared to $10.4 million in the prior year.
• Cash and Cash Equivalents: $80.7 million as of December 31, 2025, down from $118 million a year prior.
• Cash Used in Operating Activities: $14.8 million in Q4 2025, an increase from $9.1 million in Q4 2024.

2. Strategic Updates and Business Highlights

• Technology Focus: Pulse Biosciences is advancing its nanosecond pulsed field ablation (nsPFA) platform, aiming to disrupt soft tissue ablation markets.
• Clinical Development: IDE approvals for electrophysiology catheter and cardiac surgical clamp programs, with pivotal trial enrollment expected to commence soon.
• European Feasibility Studies: Progressing well with robust data supporting procedural efficiency and effectiveness.
• Vybrance Launch: Controlled launch focusing on select institutions to validate clinical and economic models, generating $264,000 in revenue in Q4.
• Intellectual Property: Added 67 patents in 2025, totaling 250 granted and 180 pending.

3. Forward Guidance and Outlook

• 2026 Focus: Plans to accelerate clinical and market development, including completing enrollment in pivotal trials for both electrophysiology and cardiac surgery.
• Revenue Growth: Anticipated expansion in the Vybrance platform and ongoing clinical data publication to support future FDA clearances.
• Partnerships: Actively pursuing strategic partnerships to enhance market entry and integration with mapping technologies.

4. Challenges and Points of Concern

• Cash Burn: Increased cash usage in operations raises concerns about financial sustainability without further funding or revenue growth.
• Regulatory Delays: The timeline for achieving FDA therapeutic clearances for new indications is projected at 4 to 8 quarters, which may hinder growth.
• Market Adoption: The transition from limited release to broader commercialization for Vybrance depends heavily on clinical data and reimbursement processes, which are still in progress.

5. Notable Q&A Insights

• Vybrance Expansion: Management emphasized a cautious approach to scaling Vybrance, focusing on quality outcomes and data-driven decisions before broader release.
• nPulse Reception: Positive feedback from the medical community regarding nPulse technology, with expectations for accelerated enrollment in upcoming studies due to strong feasibility data.
• Integration with Mapping Technologies: Plans to improve integration with existing mapping systems to enhance procedural outcomes and workflow efficiency.
• Future Data Releases: Upcoming presentations at conferences (HRS) will provide further updates on clinical outcomes and enrollment progress.

Overall, Pulse Biosciences is making significant strides in its clinical and commercial initiatives while navigating challenges related to cash flow and regulatory timelines. The company remains optimistic about its technology's potential to transform treatment paradigms in electrophysiology and soft tissue applications.